This company listing is no longer active
Nuvo Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Key information
-26.5%
Earnings growth rate
-26.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 26.3% |
| Return on equity | 178.8% |
| Net Margin | 20.9% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Nuvo Pharmaceuticals (TSE:MRV) Has A Somewhat Strained Balance Sheet
Aug 17
Is Nuvo Pharmaceuticals (TSE:MRV) Using Too Much Debt?
Sep 01Nuvo Pharmaceuticals Inc.'s (TSE:MRV) CEO Might Not Expect Shareholders To Be So Generous This Year
May 11These 4 Measures Indicate That Nuvo Pharmaceuticals (TSE:MRV) Is Using Debt Extensively
Feb 22Revenue & Expenses Breakdown
How Nuvo Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 72 | 15 | 26 | 0 |
| 30 Jun 22 | 71 | -3 | 25 | 0 |
| 31 Mar 22 | 70 | -12 | 25 | 0 |
| 31 Dec 21 | 69 | -32 | 24 | 0 |
| 30 Sep 21 | 68 | -24 | 24 | 0 |
| 30 Jun 21 | 68 | -9 | 23 | 0 |
| 31 Mar 21 | 64 | -20 | 23 | 0 |
| 31 Dec 20 | 74 | -4 | 23 | 0 |
| 30 Sep 20 | 76 | -7 | 22 | 0 |
| 30 Jun 20 | 78 | 0 | 0 | 0 |
| 31 Mar 20 | 79 | 9 | 26 | 0 |
| 31 Dec 19 | 70 | 3 | 28 | 0 |
| 30 Sep 19 | 55 | -1 | 21 | 0 |
| 30 Jun 19 | 41 | -8 | 44 | 0 |
| 31 Mar 19 | 30 | -13 | 14 | 0 |
| 31 Dec 18 | 20 | -6 | 9 | 0 |
| 30 Sep 18 | 20 | -2 | 11 | 0 |
| 30 Jun 18 | 18 | 0 | 8 | 0 |
| 31 Mar 18 | 15 | -1 | 8 | 0 |
| 31 Dec 17 | 18 | 2 | 7 | 0 |
| 30 Sep 17 | 19 | 4 | 6 | 0 |
| 30 Jun 17 | 21 | 5 | 6 | 0 |
| 31 Mar 17 | 26 | 8 | 6 | 0 |
| 31 Dec 16 | 27 | 7 | 7 | 0 |
| 30 Sep 16 | 29 | 10 | 6 | 0 |
| 30 Jun 16 | 29 | 11 | 6 | 0 |
| 31 Mar 16 | 24 | 8 | 5 | 0 |
Quality Earnings: MRV has high quality earnings.
Growing Profit Margin: MRV became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MRV has become profitable over the past 5 years, growing earnings by -26.5% per year.
Accelerating Growth: MRV has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MRV has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.3%).
Return on Equity
High ROE: Whilst MRV's Return on Equity (178.77%) is outstanding, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/17 10:23 |
| End of Day Share Price | 2023/03/15 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nuvo Pharmaceuticals Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Mark Knapp | Clarus Securities Inc. |
| null null | Eight Capital |